Dentis, Q2 Earnings 'Turnaround'... Operating Profit Up 72.8% YoY

Dentis, an implant-based digital dentistry company led by CEO Sim Gi-bong, has successfully achieved a turnaround in its performance for the second quarter of this year.

According to the disclosure made by Dentis on the 13th, the consolidated sales for the second quarter reached KRW 30.378 billion, marking the highest quarterly sales ever and representing a 28.5% increase compared to the same period last year. Operating profit was KRW 2.06 billion, and net profit was KRW 3.828 billion, showing significant growth of 72.8% and 210.6% respectively compared to the same period last year.

Regarding this, a Dentis representative stated, “As part of our global new growth strategy, we have proactively invested in new product launches, expanded overseas corporate sales coverage, and global brand marketing. As a result, we achieved strong performance in the first half of the year. We are confident that by accelerating our global market penetration through the launch of new global products certified overseas and the establishment of new subsidiaries in the second half, we will continue steady growth.”

Since last year, Dentis has diversified its business by consecutively launching various new products such as the intraosseous painless anesthesia device, dental unit chair, dental 8K 3D printer, implant mobility measuring device, and surgical room table. The company also succeeded in laying the foundation for overseas market entry by obtaining approval from the China National Medical Products Administration (NMPA) for the SQ implant and CE certification in Europe for the transparent orthodontics brand “Seraphin.”

The company showed balanced growth with domestic and export sales increasing by 19.1% and 35.9%, respectively, led by its core business sectors of dental implants and surgeries. In particular, the China subsidiary drove overseas performance growth with a 122.5% increase compared to the previous year. Additionally, growth became evident in other countries including the US and Europe, resulting in stable performance. Sales of the digital transparent orthodontic device Seraphin through its subsidiary TNS have also continued to rise steadily.

Dentis plans to respond to global demand by fully operating the newly completed implant factory, which underwent GMP inspection in the second half of this year. The new subsidiaries in India and Malaysia will also begin full-scale activities within the year after completing local certification procedures. The company plans to further accelerate overseas market expansion by considering the establishment of additional overseas subsidiaries in the future.

Furthermore, Dentis aims to complete the US Food and Drug Administration (FDA) approval and European CE certification procedures for key new products within this year and launch them globally. In particular, the surgical table, which signals the full-scale launch of Dentis’s new OR (Operation Room) total solution business, is expected to drive sales growth as a new revenue source once approval and certification are completed.